Document is current
Any future updates will be listed below
-
Authors
Bucher, Philip https://orcid.org/0000-0001-7951-1580
Brückner, Nadine https://orcid.org/0009-0008-4658-3279
Kortendieck, Jule
Grimm, Melanie
Schleicher, Jan T. https://orcid.org/0000-0002-2568-8302
Bartels, Karlotta
Hardy, Steffen
Rausch, Martina
Wurzer, Hannah https://orcid.org/0000-0001-5816-1286
Thiemann, Meike
May, Celina https://orcid.org/0009-0006-0086-3983
Mitstorfer, Mara
Letzgus, Dennis
Quach, Julia
Schneider, Carolin
Ispan, Denis A.
Gonzalez-Menendez, Irene
Jain, Nayan
Ho, Yu-Jui https://orcid.org/0000-0002-7540-024X
Chen, Jiangqing
Sánchez-Rivera, Francisco J. https://orcid.org/0000-0002-8466-8563
Sun, Jie https://orcid.org/0000-0002-5642-0560
Quintanilla-Martinez, Leticia
Trautwein, Christoph
Weigelin, Bettina https://orcid.org/0000-0003-4460-3113
Claassen, Manfred https://orcid.org/0000-0002-4583-9083
Sadelain, Michel https://orcid.org/0000-0002-9031-8025
Feucht, Judith https://orcid.org/0000-0002-8745-1079
Leibold, Josef https://orcid.org/0000-0003-2336-1987
- License Information
-
More Information
Article History
Received: 29 November 2024
Accepted: 20 November 2025
First Online: 6 January 2026
Competing interests
: P.B., M.G., J.L. and J.F. are listed as inventors on a patent application based in part on results presented in this manuscript (‘BE-CAR(E)—modified immune cells’; EP4382118). J.L., J.F., J.S., N.J. and M.S. hold other unrelated patents on CAR technologies. M.S. is an advisor for Fate Therapeutics. M.S. receives research support from Fate Therapeutics and is an advisor and has equity in Senecea Therapeutics. The other authors declare no competing interests.
